While there is interest in the potential of CDK8 inhibitor development for colon cancer, CDK8 has also become a target of interest for acute myelogenous leukemia (AML), melanoma, prostate cancer, and breast cancer [12,13,14,15]. Here, CDK8 is linked to prostate carcinoma.